Low-Dose Digoxin May Reduce Hospitalization and Death in Heart Failure Patients, UMCG Studies Show

A low dose of digoxin could help individuals with heart failure avoid hospitalization and decrease mortality risk, according to research conducted by cardiologists at the University Medical Center Groningen (UMCG). The findings, which may influence future heart failure treatment guidelines, were published in journals such as Nature Medicine and The Journal of the American Medical Association (JAMA), and were also presented at the ESC Heart Failure Congress in Barcelona.

Heart failure is a significant and increasingly prevalent health issue, with over 500,000 people in the Netherlands estimated to be affected, a number expected to rise in coming years. The condition occurs when the heart cannot pump blood effectively, leading to symptoms such as extreme shortness of breath, fatigue, and frequent hospital visits.

Digoxin Could Enhance Standard Care

Current standard treatment for heart failure typically consists of a combination of four medications, colloquially referred to as the “Fantastic Four.” Cardiologists have explored the potential of adding digoxin as a fifth treatment option. Three studies conducted by UMCG now provide evidence supporting the efficacy of low-dose digoxin.

In one significant study involving 1,000 heart failure patients across 43 centers in the Netherlands, half were administered a low dose of digoxin along with their standard treatment for an average of three years, while the other half received a placebo. Results indicated a reduction in hospital admissions for heart failure by approximately 25% among those taking digoxin. The study also found that cardiovascular disease and worsening heart failure-related deaths were lowered by 19%, although this result did not achieve statistical significance.

Meta-Analysis Strengthens Findings

The UMCG research team subsequently combined their results with data from two earlier studies through a meta-analysis, creating a more extensive patient dataset. This analysis showed a statistically significant benefit for digoxin, even for patients already receiving standard heart failure medications.

In a follow-up study of nearly 600 participants who had been assigned to either digoxin or placebo, researchers observed that stopping digoxin resulted in significantly worse outcomes during the first six weeks compared to patients who had never taken the medication; out of 288 patients, 14 experienced hospitalization or death. While these findings do not definitively prove the drug’s effectiveness, the researchers found the magnitude and timing of the effects noteworthy.

A Cost-Effective Treatment

Digoxin’s affordability is a crucial factor in its potential expansion in heart failure treatment. The medication has been a cornerstone of cardiac care for centuries, costing less than ten cents per day, in stark contrast to many newer heart failure medications priced in euros per day.

Digoxin works primarily by alleviating harmful compensatory responses in failing hearts, such as suppressing stress hormones like adrenaline. Historically, higher doses were common; however, they have proved less beneficial than low doses, which aim to reduce strain on a weakened heart muscle.

Despite the emergence of several new treatments for heart failure over the last few decades, digoxin’s use has declined, with only about 15% of heart failure patients currently receiving it. Past research suggested that low doses could offer substantial improvements compared to higher doses, yet randomized prospective studies had not systematically validated this claim until the recent UMCG research.

Funding for Future Research

Research on older, more affordable medications such as digoxin often faces funding challenges, despite their potential to lower costs while improving patient care. For this reason, Hartstichting contributed 3 million euros to this research through its partnership with ZonMw, as part of the Good Use of Medicines program.